Cargando…
A Phase I/II Study for Dose-finding, and to Investigate the Safety, Pharmacokinetics and Preliminary Efficacy of NK012, an SN-38-Incorporating Macromolecular Polymeric Micelle, in Patients with Multiple Myeloma
OBJECTIVE: Multiple myeloma (MM) is the second most common hematological cancer. An attempt to treat MM using a topoisomerase I inhibitor was made based on our previous non-clinical studies suggesting the usefulness of an SN-38 derivative. Our aim was to conduct a phase I/II study of NK012, a micell...
Autores principales: | Ri, Masaki, Suzuki, Kenshi, Iida, Shinsuke, Hatake, Kiyohiko, Chou, Takaaki, Taniwaki, Masafumi, Watanabe, Noriko, Tsukamoto, Tetsuji |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
The Japanese Society of Internal Medicine
2017
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5919849/ https://www.ncbi.nlm.nih.gov/pubmed/29225263 http://dx.doi.org/10.2169/internalmedicine.9567-17 |
Ejemplares similares
-
A phase II study of NK012, a polymeric micelle formulation of SN-38, in unresectable, metastatic or recurrent colorectal cancer patients
por: Hamaguchi, Tetsuya, et al.
Publicado: (2018) -
Comparison of two self-assembled macromolecular prodrug micelles with different conjugate positions of SN38 for enhancing antitumor activity
por: Liu, Yi, et al.
Publicado: (2015) -
Carfilzomib monotherapy in Japanese patients with relapsed or refractory multiple myeloma: A phase 1/2 study
por: Iida, Shinsuke, et al.
Publicado: (2019) -
A phase 1/2 study of carfilzomib in Japanese patients with relapsed and/or refractory multiple myeloma
por: Watanabe, Takashi, et al.
Publicado: (2016) -
Synthesis, characterization, and evaluation of mPEG–SN38 and mPEG–PLA–SN38 micelles for cancer therapy
por: Xie, Jing, et al.
Publicado: (2016)